Prevalence/NN
of/IN
aneuploidy/NN
,/,
overexpressed/JJ
ER/NN
,/,
and/CC
overexpressed/JJ
EGFR/NN
in/IN
random/JJ
breast/NN
aspirates/NNS
of/IN
women/NNS
at/IN
high/JJ
and/CC
low/JJ
risk/NN
for/IN
breast/NN
cancer/NN
./.

Breast/NN
tissue/NN
biomarkers/NNS
which/WDT
accurately/RB
predict/VBP
breast/NN
cancer/NN
development/NN
within/IN
a/DT
10/CD
year/NN
period/NN
in/IN
high/JJ
risk/NN
women/NNS
are/VBP
needed/VBN
but/CC
currently/RB
not/RB
available/JJ
./.
=====
We/PRP
initiated/VBD
this/DT
study/NN
to/TO
determine/VB
1/LS
)/)
the/DT
prevalence/NN
of/IN
one/CD
or/CC
more/JJR
breast/NN
tissue/NN
abnormalities/NNS
in/IN
a/DT
group/NN
of/IN
women/NNS
at/IN
high/JJ
risk/NN
for/IN
breast/NN
cancer/NN
,/,
and/CC
2/LS
)/)
if/IN
the/DT
prevalence/NN
of/IN
biomarker/NN
abnormalities/NNS
is/VBZ
greater/JJR
in/IN
high/JJ
risk/NN
than/IN
in/IN
low/JJ
risk/NN
women/NNS
./.
=====
Eligible/JJ
high/JJ
risk/NN
women/NNS
were/VBD
those/DT
with/IN
a/DT
first/JJ
degree/NN
relative/NN
with/IN
breast/NN
cancer/NN
,/,
prior/JJ
breast/NN
cancer/NN
,/,
or/CC
precancerous/JJ
mastopathy/NN
./.
=====
Low/JJ
risk/NN
women/NNS
were/VBD
those/DT
without/IN
these/DT
or/CC
other/JJ
major/JJ
identifiable/JJ
risk/NN
factors/NNS
./.
=====
Ductal/JJ
cells/NNS
were/VBD
obtained/VBN
via/IN
random/JJ
fine/JJ
needle/NN
aspirations/NNS
and/CC
cytologically/RB
classified/VBN
./.
=====
Biomarkers/NNS
included/VBD
DNA/NN
ploidy/NN
,/,
estrogen/NN
receptor/NN
(/(
ER/NN
)/)
,/,
and/CC
epidermal/JJ
growth/NN
factor/NN
receptor/NN
(/(
EGFR/NN
)/)
./.
=====
The/DT
prevalence/NN
of/IN
DNA/NN
aneuploidy/NN
was/VBD
30/CD
%/NN
,/,
overexpression/NN
of/IN
ER/NN
10/CD
%/NN
,/,
and/CC
overexpression/NN
of/IN
EGFR/NN
35/CD
%/NN
,/,
in/IN
the/DT
206/CD
high/JJ
risk/NN
women/NNS
whose/WP$
median/JJ
10/CD
year/NN
Gail/NN
risk/NN
(/(
projected/VBN
probability/NN
)/)
of/IN
developing/VBG
breast/NN
cancer/NN
was/VBD
4.5/CD
%/NN
./.
=====
The/DT
prevalence/NN
of/IN
aneuploidy/NN
and/CC
overexpressed/JJ
EGFR/NN
was/VBD
significantly/RB
higher/JJR
in/IN
the/DT
high/JJ
risk/NN
women/NNS
than/IN
in/IN
the/DT
25/CD
low/JJ
risk/NN
controls/NNS
(/(
p/NN
</JJR
0.002/CD
)/)
,/,
whose/WP$
median/JJ
10/CD
year/NN
Gail/NN
risk/NN
was/VBD
0.7/CD
%/NN
./.
=====
The/DT
difference/NN
in/IN
the/DT
prevalence/NN
of/IN
ER/NN
overexpression/NN
between/IN
high/JJ
and/CC
low/JJ
risk/NN
groups/NNS
was/VBD
not/RB
statistically/RB
significant/JJ
(/(
p/NN
=/JJ
0.095/CD
)/)
./.
=====
This/DT
may/MD
be/VB
due/JJ
to/TO
the/DT
low/JJ
prevalence/NN
of/IN
overexpressed/JJ
ER/NN
and/CC
the/DT
small/JJ
number/NN
of/IN
controls/NNS
./.
=====
A/DT
significant/JJ
difference/NN
was/VBD
noted/VBN
in/IN
the/DT
prevalence/NN
of/IN
one/CD
or/CC
more/JJR
abnormal/JJ
biomarkers/NNS
between/IN
the/DT
high/JJ
risk/NN
and/CC
low/JJ
risk/NN
women/NNS
(/(
p/NN
</JJR
0.001/CD
)/)
./.
=====
A/DT
large/JJ
prospective/JJ
trial/NN
is/VBZ
needed/VBN
to/TO
determine/VB
if/IN
one/CD
or/CC
more/JJR
of/IN
these/DT
biomarkers/NNS
,/,
is/VBZ
predictive/JJ
of/IN
breast/NN
cancer/NN
development/NN
./.